Bristol-Myers Squibb (NYSE:BMY) Stake Boosted by Wealth Dimensions Group Ltd.

Wealth Dimensions Group Ltd. grew its holdings in shares of Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 11.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 13,738 shares of the biopharmaceutical company’s stock after purchasing an additional 1,372 shares during the period. Wealth Dimensions Group Ltd.’s holdings in Bristol-Myers Squibb were worth $988,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its stake in Bristol-Myers Squibb by 1.6% during the third quarter. Vanguard Group Inc. now owns 199,886,585 shares of the biopharmaceutical company’s stock worth $14,209,937,000 after acquiring an additional 3,058,491 shares during the period. BlackRock Inc. grew its stake in Bristol-Myers Squibb by 2.0% during the 3rd quarter. BlackRock Inc. now owns 174,002,852 shares of the biopharmaceutical company’s stock worth $12,369,862,000 after buying an additional 3,357,590 shares during the last quarter. Dimensional Fund Advisors LP increased its position in Bristol-Myers Squibb by 1.1% in the third quarter. Dimensional Fund Advisors LP now owns 14,659,982 shares of the biopharmaceutical company’s stock worth $1,042,264,000 after buying an additional 155,845 shares during the period. Boston Partners lifted its stake in Bristol-Myers Squibb by 35.7% in the fourth quarter. Boston Partners now owns 13,794,089 shares of the biopharmaceutical company’s stock valued at $992,048,000 after buying an additional 3,627,705 shares during the last quarter. Finally, California Public Employees Retirement System lifted its stake in Bristol-Myers Squibb by 0.5% in the third quarter. California Public Employees Retirement System now owns 11,442,639 shares of the biopharmaceutical company’s stock valued at $813,457,000 after buying an additional 59,791 shares during the last quarter. 75.51% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the company. 51job reiterated a “maintains” rating on shares of Bristol-Myers Squibb in a research note on Friday, April 28th. Jefferies Financial Group began coverage on shares of Bristol-Myers Squibb in a research note on Monday, March 6th. They set a “hold” rating and a $62.00 price objective on the stock. Bank of America lifted their price objective on shares of Bristol-Myers Squibb from $82.00 to $85.00 and gave the company a “buy” rating in a research note on Friday, April 21st. Barclays cut their price objective on shares of Bristol-Myers Squibb from $66.00 to $65.00 in a research note on Monday, May 1st. Finally, StockNews.com began coverage on shares of Bristol-Myers Squibb in a research note on Thursday, May 18th. They set a “strong-buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $79.43.

Bristol-Myers Squibb Stock Performance

Shares of NYSE BMY traded down $0.65 during midday trading on Friday, hitting $63.91. 2,759,357 shares of the company’s stock were exchanged, compared to its average volume of 8,010,768. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 1.10. Bristol-Myers Squibb has a 12 month low of $63.86 and a 12 month high of $81.43. The company’s 50 day moving average price is $68.33 and its 200 day moving average price is $71.82. The firm has a market capitalization of $134.27 billion, a PE ratio of 18.74, a price-to-earnings-growth ratio of 1.34 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY – Get Rating) last released its quarterly earnings results on Thursday, April 27th. The biopharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.07. The business had revenue of $11.34 billion during the quarter, compared to the consensus estimate of $11.50 billion. Bristol-Myers Squibb had a return on equity of 51.75% and a net margin of 15.95%. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the company posted $1.96 EPS. As a group, analysts predict that Bristol-Myers Squibb will post 8.06 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, May 1st. Stockholders of record on Monday, April 10th were issued a dividend of $0.57 per share. The ex-dividend date of this dividend was Thursday, April 6th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.57%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 66.47%.

Insider Transactions at Bristol-Myers Squibb

In other news, EVP Rupert Vessey sold 50,385 shares of the business’s stock in a transaction on Wednesday, May 3rd. The stock was sold at an average price of $67.06, for a total transaction of $3,378,818.10. Following the completion of the transaction, the executive vice president now owns 47,751 shares of the company’s stock, valued at approximately $3,202,182.06. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Profile

(Get Rating)

Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.